Investigating genetic and molecular profiles of pediatric brain tumors in China

Perspective Study on Genetic Predispositions and Clinical Prognosis of Children and Adolescents With Malignant Brain Neoplasms in China

This study is trying to understand the genetic makeup of brain tumors in children to see how it affects their treatment and recovery.

Quick facts

• Study type: Observational
• Enrollment: 400 (estimated)
• Ages: 0 Years to 18 Years
• Sex: All
• Sponsor: Beijing Tiantan Hospital (Academic / other)
• Drugs / interventions: chemotherapy
• Locations: 1 site (Beijing, Beijing Municipality)
• Trial ID: NCT05672043 on ClinicalTrials.gov

What this trial studies

This observational study focuses on pediatric patients diagnosed with medulloblastomas and other malignant central nervous system tumors. It aims to collect genetic and cellular profiles through advanced techniques such as whole genome sequencing, RNA sequencing, and single-cell sequencing. Patients will be monitored post-surgery for clinical outcomes and quality of life, with follow-up assessments including MRI scans to evaluate tumor progression. The study seeks to correlate genetic characteristics with clinical prognosis to identify potential therapeutic targets.

Who should consider this trial

Good fit: Ideal candidates are children and adolescents aged 0-18 years with confirmed diagnoses of medulloblastoma or other specified malignant central nervous system tumors eligible for surgical resection.

Not a fit: Patients with major systemic illnesses or significant perioperative complications may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to improved understanding and treatment options for pediatric brain tumors.

How similar studies have performed: Other studies have shown promise in understanding genetic profiles of pediatric brain tumors, but this specific approach may offer novel insights.

Eligibility criteria

Inclusion Criteria:

\- Children and adolescents aged between 0-18 years old, diagnosed with medulloblastoma or other malignant central nervous system tumors including glioma, ependymoma, germ cell tumors,tuberous sclerosis, neuronal and neuronoglial tumors, choroid plexus tumors, atypical teratoid/rhabdoid tumors, ependymoblastoma, and medulloepithelioma;

Patients must be eligible for and receive tumor resection;

Histological examination by institutional neuro-pathological evaluation must confirmed the diagnosis of brain malignancies;

Participants consent with joining the current study and comply with follow-up visits;

The patients must have no previous radiotherapy or chemotherapy other than corticosteroids.

Exclusion Criteria:

\- Patients with major perioperative complications which lead to significant and sudden deterioration;

Patients with major systemic illness (e.g., serious infection or significant cardiac, pulmonary, hepatic, or other organ dysfunction) which might compromise the patient's ability to tolerate standard treatment or would likely interfere with overall prognosis;

Patients with major adverse events or sudden deterioration irrelevant to the current study;

Quality of tumor tissue sample did not meet the criterion for genetic sequencing and laboratory investigations;

Patients who refuse to participate in the study or who request dropping out from the study

Where this trial is running

Beijing, Beijing Municipality

• Beijing Tiantan Hosiptal — Beijing, Beijing Municipality, China (Recruiting)

Study contacts

• Principal investigator: Tao Jiang, MD — Beijing Tiantan Hospital
• Study coordinator: Tao Jiang, MD

Conditions Medulloblastoma; Central Nervous System Tumor, Pediatric; Ependymoma; Germ Cell Tumor; Glioma; Brain Tumor, Pediatric; medulloblastoma; pediatric brain tumor